Amgen vs Gilead Sciences (AMGN vs GILD)
Side by side from their SEC filings: revenue, margins, growth, returns and valuation, plus short interest, insider activity and institutional ownership.
Amgen is the larger company by revenue ($36.8B vs $29.4B) and market value ($196.1B vs $161.2B). Amgen has grown revenue faster over the last 4 fiscal years (+41.5% cumulative vs +7.8%). Gilead Sciences runs the higher operating margin (34.0% vs 24.7%). Gilead Sciences trades at the lower trailing P/E (17.7x vs 25.3x).
About Amgen
Amgen Inc discovers, develops, manufactures, and delivers medicines to treat serious diseases. The company offers products such as Repatha for cardiovascular risk, UPLIZNA for immunoglobulin G4-related disease and myasthenia gravis, and IMDELLTRA for small cell lung cancer. Amgen serves healthcare providers and patients worldwide, with a presence in about 100 countries and sales primarily through pharmaceutical wholesalers and direct-to-patient channels.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that develops and markets medicines to treat life-threatening diseases such as HIV, viral hepatitis, COVID-19, and cancer. Its product portfolio includes oral antiretroviral therapies for HIV, treatments for liver diseases like hepatitis B and C, oncology therapies including CAR T-cell treatments, and antifungal and antiviral drugs. The company serves healthcare providers and patients worldwide through its commercial operations in over 35 countries.
Head to head (AMGN FY2025 vs GILD FY2025)
| Metric | AMGNFY2025 | GILDFY2025 |
|---|---|---|
| Revenue | $36.75B | $29.44B |
| Revenue growth (YoY) | 10.0% | 2.4% |
| Gross margin | 67.2% | 78.8% |
| Operating margin | 24.7% | 34.0% |
| Net margin | 21.0% | 28.9% |
| Net income | $7.71B | $8.51B |
| Diluted EPS | $14.23 | $6.78 |
| FCF margin | 22.0% | 32.1% |
| ROE | 89.1% | 37.6% |
| Debt / equity | 5.8× | 1.0× |
| Market cap | $196.12B | $161.19B |
| P/E (TTM) | 25.3× | 17.7× |
Fundamentals are from each company’s SEC filings (AMGN FY2025, GILD FY2025). P/E and market cap are derived from recent market prices and update daily.
Five-year trend (as reported)
| Revenue | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| AMGN | $25.98B | $26.32B | $28.19B | $33.42B | $36.75B |
| GILD | $27.30B | $27.28B | $27.12B | $28.75B | $29.44B |
Peer standing
Where each company ranks among the 71 biotech companies, on the same scale. Each figure is ranked only against peers that report it. Percentiles describe position in the distribution, not a rating.
| Metric | AMGN | GILD |
|---|---|---|
| Gross margin | 67.2%54th percentile of 14 | 78.8%85th percentile of 14 |
| Operating margin | 24.7%70th percentile of 31 | 34.0%80th percentile of 31 |
| Net margin | 21.0%68th percentile of 32 | 28.9%81st percentile of 32 |
| FCF margin | 22.0%74th percentile of 28 | 32.1%81st percentile of 28 |
| Revenue growth (YoY) | +10.0%40th percentile of 64 | +2.4%33rd percentile of 64 |
| ROE | 89.1%93rd percentile of 61 | 37.6%92nd percentile of 61 |
| P/E (TTM) | 25.3×70th percentile of 21 | 17.7×50th percentile of 21 |
| Debt / equity | 5.78×94th percentile of 19 | 0.98×78th percentile of 19 |
| Short interest (days to cover) | 3.93d39th percentile of 71 | 2.66d23rd percentile of 71 |
Short interest
| FINRA settlement data | AMGN | GILD |
|---|---|---|
| Shares sold short | 12.9M | 25.5M |
| Change vs prior settlement | +5.5% | +6.8% |
| Days to cover | 3.93 | 2.66 |
| As of settlement | 2026-06-30 | 2026-06-30 |
Source: FINRA Consolidated Short Interest. FINRA is the owner and source of the FINRA-supplied data; republishing or redistributing it is not permitted. Not presented as a percentage of float. No FINRA endorsement of this product is implied.
Insider activity (last 90 days)
| Form 4 open-market activity | AMGN | GILD |
|---|---|---|
| Buys | 0 | 0 |
| Sells | 1 ($400,451) | 18 ($10.8M) |
Open-market purchases and sales reported on SEC Form 4 (grants, exercises and tax withholding excluded). For context, about 16% of covered companies saw any open-market insider buy in a 90-day window.
Held by the same investors
8 tracked 13F managers hold both Amgen and Gilead Sciences as of their latest quarterly filings: AQR Capital Management, Bridgewater Associates, Citadel Advisors, D. E. Shaw, Dodge & Cox, Gotham Asset Management, Millennium Management, Two Sigma Investments. See which superinvestors hold your own portfolio with the smart money checker.
Go deeper
AMGN vs BIIBAMGN vs EXELAMGN vs MRNAAMGN vs NBIXAMGN vs RVMDAMGN vs TECHAll biotech stocks →All comparisons →
Track AMGN and GILD
Get an alert when either company files something material, see which superinvestors own them, and ask their filings a question with cited answers.
Start monitoring freeIncludes one free filing-grounded research answer. Or check your whole portfolio, no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filings before relying on them. Comparisons are descriptive (higher or lower on a reported figure), not a rating or a recommendation. Informational only. Not investment advice.